ArticleAmerican journal of translational research2025
A predictive model for anlotinib-osimertinib efficacy in advanced non-small cell lung cancer with acquired resistance: circulating tumor DNA and angiogenesis markers.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo develop a predictive model for the efficacy of anlotinib combined with osimertinib in treating advanced non-small cell lung cancer (NSCLC) with acquired resistance, based on circulating tumor DNA (ctDNA) clearance and angiogenesis markers.
methodsWe retrospectively analyzed data from 378 patients with acquired resistance advanced NSCLC treated at Shanghai University Mengchao Cancer Hospital between November 2020 and October 2022. Patients were divided into a monotherapy group (n=181, receiving osimertinib alone) and a combination therapy group (n=197, receiving anlotinib plus osimertinib). The combination therapy group was further stratified into two subgroups based on progression-free survival (PFS): better efficacy (PFS ≥16 months) and poorer efficacy (PFS <16 months). Venous blood samples were collected before and after two treatment cycles for ctDNA detection using next-generation sequencing (NGS) and measurement of angiogenesis markers using electrochemiluminescence immunoassays. Multivariate logistic regression was employed to identify independent predictors, and a nomogram predictive model was constructed and validated.
resultsThe combination therapy group demonstrated significantly longer PFS and overall survival compared to the monotherapy group. After two treatment cycles, the combination therapy group showed a significant reduction in ctDNA levels, variant allele frequency (VAF), and a higher clearance rate of the T790M mutation. Additionally, angiogenesis markers were significantly lower in the combination therapy group post-treatment (all P<0.05). Multivariate logistic regression identified significant predictors of poor therapeutic effect. The nomogram model exhibited excellent predictive performance, with an AUC of 0.912 in the training set and 0.959 in the test set.
conclusionThe developed nomogram reliably predicts the efficacy of anlotinib combined with osimertinib in treating acquired resistance NSCLC, offering valuable guidance for personalized treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.